secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2022-08-03T23:59:59+00:00
Accession:  0001171843-22-005312
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anika Q2 rev $39.7M (+4%); net loss ($2.8M) vs prior profit $6.5M
-----------------------------------------------------------------

- Q2 revenue $39.7M (+4% YoY); OA Pain Mgmt $25.7M (+6%), Joint Preservation $12.1M (+2%).
- Net loss ($2.8M) or ($0.20)/share vs prior net income $6.5M ($0.45); adjusted net loss ($1.6M) or ($0.12)/share.
- Adjusted EBITDA $4.4M vs $6.1M; cash $91.4M, no debt.
- X-Twist Fixation System FDA 510(k) clearance received; limited market release on schedule for 2H 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000117184322005312/0001171843-22-005312-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000117184322005312/f8k_080322.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-005312

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer